Applications of computational toxicology methods at the Agency for Toxic Substances and Disease Registry.

In its efforts to provide consultations to state and local health departments, other federal agencies, health professionals, and the public on the health effects of environmental pollutants, the Agency for Toxic Substances and Disease Registry relies on the latest advances in computational toxicology. The computational toxicology laboratory at the agency is continually engaged in developing and applying models for decision-support tools such as physiologically based pharmacokinetic (PBPK) models, benchmark dose (BMD) models, and quantitative structure-activity relationship (QSAR) models. PBPK models are suitable for connecting exposure scenarios to biological indicators such as tissue dose or end point response. The models are used by the agency to identify the significance of exposure routes in producing tissue levels of possible contaminants for people living near hazardous waste sites. Additionally, PBPK models provide a credible scientific methodology for route-to-route extrapolations of health guidance values, which are usually determined from a very specific set of experiments. Also, scientists at the computational toxicology laboratory are using PBPK models for advancing toxicology research in such areas as joint toxicity assessment and child-based toxicity assessments. With BMD modeling, all the information embedded in an experimentally determined dose-response relationship is used to estimate, with minimum extrapolations, human health guidance values for environmental substances. Scientists in the laboratory also rely on QSAR models in the many cases where consultations from the agency are reported for chemicals that lack adequate experimental documentation.

[1]  R S Yang,et al.  Some current approaches for studying combination toxicology in chemical mixtures. , 1996, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[2]  R. Lutz,et al.  A preliminary pharmacokinetic model for several chlorinated biphenyls in the rat. , 1977, Drug metabolism and disposition: the biological fate of chemicals.

[3]  J. Wagner,et al.  History of pharmacokinetics. , 1981, Pharmacology & therapeutics.

[4]  C J Portier,et al.  Using structural information to create physiologically based pharmacokinetic models for all polychlorinated biphenyls. II. Rates of metabolism. , 1998, Toxicology and applied pharmacology.

[5]  K. Enslein,et al.  Prediction of probability of carcinogenicity for a set of ongoing NTP bioassays. , 1990, Mutagenesis.

[6]  F. A. Smith,et al.  Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. , 1987, Toxicology and applied pharmacology.

[7]  C DeRosa,et al.  Using structural information to create physiologically based pharmacokinetic models for all polychlorinated biphenyls. , 1997, Toxicology and applied pharmacology.

[8]  K Enslein,et al.  Assessment of developmental toxicity potential of chemicals by quantitative structure-toxicity relationship models. , 1995, Chemosphere.

[9]  M E Andersen,et al.  Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment. , 1995, Toxicology letters.

[10]  H. B. Matthews,et al.  Using Structural Information to Create Physiologically Based Pharmacokinetic Models for All Polychlorinated Biphenyls: I. Tissue:Blood Partition Coefficients , 1997 .